Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy

Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy  AV-001 was Safe and Well-Tolerated in Healthy Volunteers  Vasomune plans to initiate a Phase 2a proof-of-concept study…

Continue Reading Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy

Vasomune is Pleased to Announce the Government of Canada’s Investment in AV-001 Targeting COVID-19

Vasomune is very pleased to announce that the company has received a substantial investment on behalf of the Government of Canada through the National Research Council (NRC) for Vasomune's continued…

Continue Reading Vasomune is Pleased to Announce the Government of Canada’s Investment in AV-001 Targeting COVID-19

Vasomune Announces Initiation of the First-in-Human Clinical Trial of a Potential Vascular Normalization COVID-19 Treatment

First subjects have been dosed in Phase 1 study of AV-001, a novel first-in-class therapeutic Should the Phase 1 results show AV-001 is safe and well-tolerated, Vasomune will initiate a…

Continue Reading Vasomune Announces Initiation of the First-in-Human Clinical Trial of a Potential Vascular Normalization COVID-19 Treatment

Vasomune Announces FDA Allowance of IND Application for AV-001 for the Treatment of Hospitalized Patients with COVID-19

TORONTO, Ontario - (Business Wire) – November 12, 2020 - Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced today the U.S. Food and Drug Administration (FDA) has allowed its Investigational…

Continue Reading Vasomune Announces FDA Allowance of IND Application for AV-001 for the Treatment of Hospitalized Patients with COVID-19

Learn More About Vasomune’s Partnership with University of Iowa Pharmaceuticals’ COVID-19 Drug Manufacturing

Vasomune Therapeutics has been working with University of Iowa Pharmaceuticals (UIP) through a strategic partnership toward the manufacture of AV-001, a biopharmaceutical therapeutic that treats acute respiratory distress syndrome (ARDS)…

Continue Reading Learn More About Vasomune’s Partnership with University of Iowa Pharmaceuticals’ COVID-19 Drug Manufacturing

Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19

Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19 TORONTO, Ontario -…

Continue Reading Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001 for the Treatment of ALI/ARDS of Any Cause, Including COVID-19